The microbiome analysis market is projected to grow from USD 1.45 billion in 2025 to USD 4.84 billion by 2035 because research keeps linking the microbiome to human health and disease, sequencing costs keep falling, and drug developers and consumers increasingly use microbiome data. Growth of shotgun metagenomics, microbiome therapeutics development, clinical and consumer testing, multi-omics and AI analysis support strong growth, lifting the market to USD 2.65 billion by 2030 and sustaining a CAGR of 12.80% from 2026 to 2035.
Analyst View: We built the estimate from the number of microbiome samples analysed by product and service, technology, application, end use and region, multiplied by average prices per sample for consumables, instrument use and services. Sample numbers reflect research funding, clinical trials and testing activity, while prices reflect the shift from 16S to deeper shotgun sequencing. The total was cross-checked against the microbiome-related revenues of leading tool and service providers and against published estimates, which places our base year slightly above the highest credible comparable figure. The growth rate reflects strong growth in metagenomics and clinical use, which we judge supports a slightly higher rate than comparable estimates, moderated by data complexity and limited standardization.
The microbiome analysis market is driven by growing recognition of the microbiome's role in disease development and treatment outcomes. Declining sequencing costs, increasing investment in microbiome therapeutics, rising consumer interest in gut health, and AI-driven improvements in microbial data analysis are further expanding demand across research and clinical applications.
Market growth is constrained by the complexity of microbiome data interpretation and the lack of standardized testing and analytical protocols. Limited clinical validation, shortages of skilled bioinformaticians, and inadequate reimbursement coverage further restrict the adoption of microbiome testing in routine healthcare and limit broader commercial applications.
Growing demand for clinical diagnostics and companion testing presents significant opportunities for microbiome analysis providers. Increasing use of microbial biomarkers in drug development, expanding research investments across Asia Pacific, standardized analytical pipelines, and emerging applications in food, agriculture, and livestock research are expected to create new growth avenues.
Note: 2025 is the base year; 2035 values are forecasts.
Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
Consumables: This segment accounted for 46.50% (USD 0.67 billion) of the microbiome analysis market in 2025 and is projected to reach USD 2.08 billion by 2035, expanding at a CAGR of 11.87% from 2026 to 2035. Consumables include sample collection and stabilization kits, DNA and RNA extraction kits, library preparation kits, and sequencing reagents. They lead because every sample analyzed consumes them.
Growth is supported by increasing outsourcing of sequencing, bioinformatics, and data interpretation activities to specialized service providers by academic researchers and pharmaceutical companies.
Instruments include sequencers, PCR systems and automated sample preparation systems used in microbiome laboratories.
Note: 2025 is the base year; 2035 values are forecasts.
Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
16S rRNA Sequencing: This segment accounted for 49.00% (USD 0.71 billion) of the microbiome analysis market in 2025 and is projected to reach USD 2.15 billion by 2035, expanding at a CAGR of 11.65% from 2026 to 2035. 16S rRNA sequencing reads a marker gene to identify bacteria at low cost. It leads because it is widely used for large research studies and screening.
Growth is supported by declining sequencing costs and its ability to identify bacteria, viruses, and fungi at species and strain levels while providing deeper insights into microbial functions and therapeutic applications.
Note: 2025 is the base year; 2035 values are forecasts.
Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
Research: Dominating the application landscape with a 62.50% share (USD 0.91 billion) in 2025, the segment is projected to reach USD 2.73 billion by 2035, growing at a CAGR of 11.63%. Its leading position reflects widespread use of microbiome analysis in academic investigations and discovery research exploring microbial interactions with human health, food systems, and the environment.
Disease diagnosis and therapeutics is growing faster as microbiome tests enter clinical practice, and drug developers use microbiome analysis in trials of microbiome therapies, immunotherapies and other drugs.
Note: 2025 is the base year; 2035 values are forecasts.
Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
Academic & Research Institutes: This segment accounted for 39.00% (USD 0.57 billion) of the microbiome analysis market in 2025 and is projected to reach USD 1.79 billion by 2035, expanding at a CAGR of 12.22% from 2026 to 2035. Academic and research institutes are the largest users because of large publicly funded microbiome research programmes.
Pharmaceutical and biotechnology companies use microbiome analysis for drug discovery, microbiome therapeutics, and clinical trial biomarkers.
Clinical laboratories and others include diagnostic laboratories and consumer testing companies.
Rising outsourcing of microbiome research, clinical studies, and microbiome therapeutics manufacturing by pharmaceutical and biotechnology companies is accelerating segment growth.
Analyst View: Segment values were allocated by matching sample volumes and prices to products and services, technologies, applications and end uses, using provider portfolios and research activity. Consumables, 16S sequencing, research and academic users lead. We expect services, shotgun metagenomics, clinical and therapeutic applications and CROs to gain share.
| Region | 2025 Share | 2025 Value (USD Billion) | 2035 Value (USD Billion) | CAGR 2026–2035 |
| North America | 42.70% | 0.62 | 1.94 | 12.09% |
| Europe | 27.00% | 0.39 | 1.27 | 12.49% |
| Asia Pacific | 22.00% | 0.32 | 1.23 | 14.49% |
| Latin America | 5.00% | 0.07 | 0.24 | 12.49% |
| Middle East & Africa | 3.30% | 0.05 | 0.16 | 12.49% |
Note: 2025 is the base year; 2035 values are forecasts.
Sources: Expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
North America: This region accounted for 42.70% (USD 0.62 billion) of the microbiome analysis market in 2025 and is projected to reach USD 1.94 billion by 2035, expanding at a CAGR of 12.09% from 2026 to 2035. North America is the largest region because of large public and private microbiome research funding, many microbiome therapeutics and testing companies and strong sequencing infrastructure.
Europe: The European market represented 27.00% (USD 0.39 billion) of the microbiome analysis market in 2025 and is projected to reach USD 1.27 billion by 2035, expanding at a CAGR of 12.49% from 2026 to 2035. Europe has strong microbiome research consortia, specialized microbiome service providers such as Cmbio, and growing clinical interest in microbiome diagnostics.
Asia Pacific: Asia Pacific held a market value of 22.00% (USD 0.32 billion) of the microbiome analysis market in 2025 and is projected to reach USD 1.23 billion by 2035, expanding at a CAGR of 14.49% from 2026 to 2035. Asia Pacific is the fastest-growing region because of large sequencing capacity in China, growing microbiome research in Japan, South Korea, Australia and India, and consumer testing companies.
Latin America: Latin America's market stood at 5.00% (USD 0.07 billion) of the microbiome analysis market in 2025 and is projected to reach USD 0.24 billion by 2035, expanding at a CAGR of 12.49% from 2026 to 2035. Latin America is supported by growing academic microbiome research in Brazil and Mexico.
Middle East & Africa: This region accounted for 3.30% (USD 0.05 billion) of the microbiome analysis market in 2025 and is projected to reach USD 0.16 billion by 2035, expanding at a CAGR of 12.49% from 2026 to 2035. The Middle East and Africa are supported by population genomics and research investment in Gulf countries.
Analyst View: Regional shares were built from microbiome analysis activity in each region. North America leads because of its research funding and companies. We assign Asia Pacific the highest growth premium because sequencing capacity and research are expanding fastest there.
| Rank | Company Name | Market-Specific Revenue (USD Billion) | 2025 Share | Key Products / Business | Headquarters |
| 1 | Illumina | 0.17 | 11.72% | Sequencing systems and reagents | United States |
| 2 | Thermo Fisher Scientific | 0.12 | 8.28% | Extraction kits, sequencing and qPCR | United States |
| 3 | QIAGEN | 0.09 | 6.21% | Microbiome extraction kits and bioinformatics | Netherlands |
| 4 | Zymo Research | 0.06 | 4.14% | Microbiome kits and services | United States |
| 5 | Novogene | 0.06 | 4.14% | Microbiome sequencing services | China |
| 6 | BGI Genomics | 0.05 | 3.45% | Microbiome sequencing services | China |
| 7 | Viome | 0.04 | 2.76% | Consumer microbiome testing | United States |
| 8 | Oxford Nanopore Technologies | 0.03 | 2.07% | Long-read sequencing | United Kingdom |
| 9 | Cmbio | 0.03 | 2.07% | Microbiome CRO services | Denmark |
| 10 | Microba Life Sciences | 0.02 | 1.38% | Metagenomic testing | Australia |
Note: Company revenues and shares are 2025 estimates.
Sources: Company press releases, expert interviews, secondary sources, Precedence Research database and Precedence Research analysts.
Illumina led the microbiome analysis market with an estimated 11.72% (USD 0.17 billion) of 2025 revenue, followed by Thermo Fisher Scientific at 8.28% (USD 0.12 billion) and QIAGEN at 6.21% (USD 0.09 billion). Illumina leads because most microbiome sequencing runs on its platforms. Thermo Fisher Scientific supplies extraction kits, sequencing and qPCR products, and QIAGEN offers microbiome extraction kits and bioinformatics software. Zymo Research, Novogene, BGI Genomics, Viome, Oxford Nanopore Technologies, Cmbio and Microba Life Sciences compete through microbiome kits and services, sequencing services, consumer testing, long-read sequencing, CRO services and metagenomic testing.
The top 10 companies accounted for an estimated 46.21% (USD 0.67 billion) of 2025 revenue, while the remaining 53.79% (USD 0.78 billion) was shared among many specialized microbiome laboratories, bioinformatics firms, and consumer testing companies. The microbiome analysis market is fragmented, and competition focuses on accuracy, depth of analysis, turnaround time, bioinformatics and reference databases, regulatory compliance, and price. Specialist providers are consolidating to offer end-to-end services from sample collection to analysis.
The microbiome analysis ecosystem links collection and extraction kit makers and sequencing platform providers with service laboratories, bioinformatics providers and research, clinical and consumer users.
| Ecosystem Stage | Role in the Market | Key Companies |
| Collection & Prep Kits | Collect and extract samples | Zymo Research, QIAGEN, DNA Genotek, Thermo Fisher |
| Sequencing Platforms | Read microbial DNA | Illumina, Oxford Nanopore, PacBio, MGI |
| Service Laboratories | Run sequencing and analysis | Novogene, BGI, Cmbio, Microba |
| Bioinformatics | Interpret microbiome data | Analysis platforms and databases |
| Users | Apply results | Researchers, drug developers, clinicians, consumers |
Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
The Towards Healthcare Companies Quadrant positions key participants in the microbiome analysis market by market strength, reflecting revenue scale, market share and geographic reach, and by innovation and growth strategy, reflecting product portfolio breadth, R&D intensity and partnerships. Positions reflect each company's estimated 2025 microbiome revenue analysis and our assessment of its technology, services, and innovation.
Sources: Company press releases, expert interviews, secondary sources, Towards Healthcare database and Towards Healthcare analysts.
Leaders: Illumina, Thermo Fisher Scientific, QIAGEN, Zymo Research, Novogene and BGI Genomics combine large microbiome-related revenue with broad platforms and products.
Innovators: Viome, Oxford Nanopore Technologies, Cmbio and Microba Life Sciences bring specialised microbiome services and technologies.
By Product & Service
By Technology
By Application
By End Use
By Region
The microbiome analysis market was defined as consumables, instruments, and services used to analyze microbial communities through sequencing and other analytical methods worldwide. The 2025 base-year estimate was developed using the volume of microbiome samples analyzed across products and services, technologies, applications, end uses, and regions, multiplied by average prices per sample. The resulting market size was cross-validated against microbiome-related revenues of leading equipment and service providers.
Segment, regional, and company-level values were allocated based on product and service offerings, technologies, applications, end uses, and regional activity. Key estimates were verified against company disclosures, regulatory and industry data, and published third-party estimates, while unreconciled inputs were excluded. All segment, regional, and company figures were aligned to the same 2025 base year, and the 2026–2035 forecast was calculated using a consistent CAGR and subsequently validated.
Analyst View: The microbiome analysis market is a fast-growing segment of life science tools and services, moving from research into clinical and consumer use. Our estimate links demand to sample volumes and prices, so the forecast follows research funding, drug development and testing adoption. The main upside comes from shotgun metagenomics and clinical applications, while the main risks are data complexity and limited standardization.
